Two competing bills that could significantly reshape the hemp industry in Massachusetts are both set to receive a public hearing on July 9. The Joint Committee on Agriculture has scheduled a hearing from 1:00 PM to 5:00 PM in Room A-1 to consider both House Bill 117 and Senate Bill 54, each filed in February …
Nebraska: Judge Dismisses Lawsuit Challenging Medical Marijuana Law
A Nebraska judge has dismissed a lawsuit that sought to overturn the state’s medical marijuana law approved by voters through initiatives 437 and 438. The lawsuit was filed by former State Senator John Kuehn (R), who argued that because marijuana remains illegal under federal law, the initiatives should be deemed unconstitutional. The suit named Governor …
Study: Hemp Seed Oil Significantly Improves Atopic Dermatitis (Eczema) Symptoms
New research published in Current Issues in Pharmacy and Medical Sciences found that a hemp seed oil-based topical emulsion led to a marked improvement in symptoms of atopic dermatitis. Researchers from the Medical University of Silesia, University of Opole, and De Montfort University in the UK conducted a three-month interventional study on a 23-year-old male …
Study: 37% of California Adults Have Used Marijuana Recently, Many Daily and for Mental Health Benefits
A new study finds that over a third of adults in California currently use marijuana, with many reporting daily consumption and perceived health benefits, particularly for mental and emotional well-being. Published in the peer-reviewed journal Cannabis and Cannabinoid Research, the study draws on data from the Impact 64 study and includes responses from over 15,000 …
Clinical Trial: Full-Spectrum Cannabis Extract Improves Core Symptoms of Rett Syndrome and Reduces Caregiver Burden
A Phase I/II clinical trial published today by the Journal of Paediatrics and Child Health has found that NTI164, a low-THC full-spectrum cannabis extract, can significantly improve the core symptoms associated with Rett syndrome (RTT), a rare neurodevelopmental disorder. Conducted over 12 weeks, the open-label trial administered NTI164 to 11 girls between the ages of …
Nebraska Medical Cannabis Commission Bans Cannabis Flower and Edibles in Approved Regulations
The Nebraska Medical Cannabis Commission has given approval to a set of licensing and product regulations for marijuana businesses, following a public meeting held today in Lincoln. The commission, meeting just days ahead of a July 1 deadline mandated by voters, adopted strict guidelines on what forms of medical marijuana will be allowed once sales …
Michigan Lawmaker Files Bill to Decriminalize Psilocybin and Psilocyn for PTSD Patients
State Representative Mike McFall (D) has introduced legislation that would allow adults diagnosed with post-traumatic stress disorder (PTSD) to legally possess small amounts of psilocybin and psilocyn, the psychedelic compounds found in magic mushrooms. The bill, filed yesterday with six Democratic cosponsors, has been referred to the House Committee on Families and Veterans. House Bill …
Aurora Cannabis Expands Compassionate Pricing Program, Raising Income Eligibility to CA$60,000
Aurora Cannabis has expanded its compassionate pricing program for medical marijuana patients in Canada, increasing the income eligibility threshold from $40,000 to $60,000 CAD annually. The change is intended to make medical marijuana more accessible to a broader range of patients. “As over half of the country’s adult population fits within this income threshold, our …
California’s Cannabis Excise Tax to Increase to 19% Starting Tuesday, July 1
California’s marijuana excise tax is set to rise from 15% to 19% on Tuesday, July 1. The automatic hike was triggered by a decline in cannabis excise revenue, despite industry warnings that the increase will further burden legal businesses already struggling to compete with the illicit market. The California Department of Tax and Fee Administration …
Tilray Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations
Tilray Medical, a division of Tilray Brands, Inc., today announced the publication of a study that focuses on comparing the bioavailability of different cannabinoid formulations, “taking a step forward in our understanding of medical cannabis.” The study aimed to assess the pharmacokinetic parameters and relative bioavailability of two D9-tetrahydrocannabinol: cannabidiol (THC:CBD) formulations. (A) An orally …
